EUVIMEDEUVIMED entdecken
VergleichsstudieMetaanalyseSystematische Übersicht

Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta‐analysis

M Meritxell Roca Mora iD, Farhan Afzal, Catharina Ribeiro Guimaraes, Luisa Marin Cunha, Amanda Godoi, Patrícia Marcolin, Andrés Valenzuela S

APMIS · 2024

DOI: 10.1111/apm.13472 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift APMIS, 2024. Verfasst von M Meritxell Roca Mora und 6 weiteren Autor:innen. Beteiligte Einrichtung: International University of Catalonia, Barcelona, Spain. Hauptthemen laut MEDLINE: Nitriles, Polycythemia Vera, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to have lower thromboembolism rates compared to placebo in polycythemia vera (PV) patients. This meta‐analysis evaluates ruxolitinib's efficacy and safety against best available therapy (BAT) in patients with PV and in hydroxyurea‐resistant/intolerant PV patients. A comprehensive literature search was conducted up to November 2023. We compared ruxolitinib and BAT for efficacy and safety endpoints. Six studies involving 1061 patients were analyzed, with 620 on BAT and 441 on ruxolitinib. Ruxolitinib showed higher hematocrit control (p = 0.015) and treatment response (p = 0.04) compared to BAT. It also significantly improved Myeloproliferative Neoplasms‐Symptom Assessment Form scores (MPN‐SAF) (p < 0.01). Additionally, patients with PV treated with ruxolitinib had higher rates of nonmelanoma skin cancer (p < 0.01). In subgroup analyses focusing on patients resistant or intolerant to hydroxyurea, ruxolitinib maintained its efficacy, significantly improving treatment response (p < 0.01) and significant improvements in MPN‐SAF (p = 0.02) score when compared to BAT. The safety profile was consistent with the overall analyses, showing significantly reduced thromboembolism rates (p = 0.04), increased rates of anemia (p = 0.01), and increased herpes zoster infections (p = 0.02). Ruxolitinib outperforms BAT in PV and patients with PV‐resistant or intolerant to hydroxyurea, offering better hematocrit control and reducing symptomatic burden and thromboembolism risk. Yet, it is associated with higher rates of anemia, herpes infection, and skin cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitrilesPolycythemia VeraPyrazolesPyrimidinesHumansHematocritHydroxyureaJanus Kinase 1Janus Kinase 2Treatment Outcome

Stichwörter der Autor:innen

JAK inhibitorPolycythemia verahydroxyureamyeloproliferative neoplasmruxolitinib

Substanzen

HydroxyureaJanus Kinase 1Janus Kinase 2NitrilesPyrazolesPyrimidinesruxolitinib

Autor:innen und Institutionen

  • International University of Catalonia, Barcelona, Spain.
  • Faisalabad Medical University, Faisalabad, Pakistan.
  • Universidade Federal de Ouro Preto, Ouro Preto, Brazil.
  • Centro Universitário Lusíada, Santos, Brazil.
  • Cardiff School of Medicine, Cardiff, Wales, UK.
  • Federal University of the Southern Border, Passo Fundo, Brazil.

ORCID-Profile: M Meritxell Roca Mora

Zitieren

APA

Roca Mora, M. M., Afzal, F., Guimaraes, C. R., Cunha, L. M., Godoi, A., Marcolin, P., & Valenzuela S, A. (2024). Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta‐analysis. APMIS. https://doi.org/10.1111/apm.13472

Vancouver

Roca Mora MM, Afzal F, Guimaraes CR, Cunha LM, Godoi A, Marcolin P, et al. Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta‐analysis. APMIS. 2024. doi:10.1111/apm.13472

BibTeX
@article{RocaMora2024,
  author = {Roca Mora, M Meritxell and Afzal, Farhan and Guimaraes, Catharina Ribeiro and Cunha, Luisa Marin and Godoi, Amanda and Marcolin, Patrícia and Valenzuela S, Andrés},
  title = {Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta‐analysis},
  journal = {APMIS},
  year = {2024},
  doi = {10.1111/apm.13472}
}
Kostenlos starten →